Sandostatin for control of catheter drainage of pancreatic pseudocyst

Jamie S Barkin, D. K. Reiner, E. Deutch

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

Primary treatment for pancreatic pseudocyst is evolving from surgical intervention to needle aspiration with catheter drainage. The latter treatment results in a similar rate of resolution but has less patient morbidity. This study evaluated the adjuvant role of Sandostatin, which inhibits basal and stimulated pancreatic secretion, in the management of three patients with pancreatic pseudocysts who had prolonged catheter drainage subsequent to percutaneous drainage. Inhibition of secretion occurred in all three patients, as evidenced by decrease in catheter output, which allowed the catheter to be removed. All three patients have remained asymptomatic for 9, 10, and 15 months, respectively. In summary, Sandostatin decreased persistent catheter drainage from chronic pancreatic pseudocysts.

Original languageEnglish
Pages (from-to)245-248
Number of pages4
JournalPancreas
Volume6
Issue number2
StatePublished - Jan 1 1991

Fingerprint

Pancreatic Pseudocyst
Octreotide
Drainage
Catheters
Needles
Morbidity
Therapeutics

Keywords

  • Catheter drainage
  • Needle aspiration
  • Pancreatic pseudocyst
  • Pancreatic secretion
  • Sandostatin

ASJC Scopus subject areas

  • Endocrinology
  • Gastroenterology

Cite this

Sandostatin for control of catheter drainage of pancreatic pseudocyst. / Barkin, Jamie S; Reiner, D. K.; Deutch, E.

In: Pancreas, Vol. 6, No. 2, 01.01.1991, p. 245-248.

Research output: Contribution to journalArticle

Barkin, JS, Reiner, DK & Deutch, E 1991, 'Sandostatin for control of catheter drainage of pancreatic pseudocyst', Pancreas, vol. 6, no. 2, pp. 245-248.
Barkin, Jamie S ; Reiner, D. K. ; Deutch, E. / Sandostatin for control of catheter drainage of pancreatic pseudocyst. In: Pancreas. 1991 ; Vol. 6, No. 2. pp. 245-248.
@article{3323220ac8514fb0bd9f08789f1c6734,
title = "Sandostatin for control of catheter drainage of pancreatic pseudocyst",
abstract = "Primary treatment for pancreatic pseudocyst is evolving from surgical intervention to needle aspiration with catheter drainage. The latter treatment results in a similar rate of resolution but has less patient morbidity. This study evaluated the adjuvant role of Sandostatin, which inhibits basal and stimulated pancreatic secretion, in the management of three patients with pancreatic pseudocysts who had prolonged catheter drainage subsequent to percutaneous drainage. Inhibition of secretion occurred in all three patients, as evidenced by decrease in catheter output, which allowed the catheter to be removed. All three patients have remained asymptomatic for 9, 10, and 15 months, respectively. In summary, Sandostatin decreased persistent catheter drainage from chronic pancreatic pseudocysts.",
keywords = "Catheter drainage, Needle aspiration, Pancreatic pseudocyst, Pancreatic secretion, Sandostatin",
author = "Barkin, {Jamie S} and Reiner, {D. K.} and E. Deutch",
year = "1991",
month = "1",
day = "1",
language = "English",
volume = "6",
pages = "245--248",
journal = "Pancreas",
issn = "0885-3177",
publisher = "Lippincott Williams and Wilkins",
number = "2",

}

TY - JOUR

T1 - Sandostatin for control of catheter drainage of pancreatic pseudocyst

AU - Barkin, Jamie S

AU - Reiner, D. K.

AU - Deutch, E.

PY - 1991/1/1

Y1 - 1991/1/1

N2 - Primary treatment for pancreatic pseudocyst is evolving from surgical intervention to needle aspiration with catheter drainage. The latter treatment results in a similar rate of resolution but has less patient morbidity. This study evaluated the adjuvant role of Sandostatin, which inhibits basal and stimulated pancreatic secretion, in the management of three patients with pancreatic pseudocysts who had prolonged catheter drainage subsequent to percutaneous drainage. Inhibition of secretion occurred in all three patients, as evidenced by decrease in catheter output, which allowed the catheter to be removed. All three patients have remained asymptomatic for 9, 10, and 15 months, respectively. In summary, Sandostatin decreased persistent catheter drainage from chronic pancreatic pseudocysts.

AB - Primary treatment for pancreatic pseudocyst is evolving from surgical intervention to needle aspiration with catheter drainage. The latter treatment results in a similar rate of resolution but has less patient morbidity. This study evaluated the adjuvant role of Sandostatin, which inhibits basal and stimulated pancreatic secretion, in the management of three patients with pancreatic pseudocysts who had prolonged catheter drainage subsequent to percutaneous drainage. Inhibition of secretion occurred in all three patients, as evidenced by decrease in catheter output, which allowed the catheter to be removed. All three patients have remained asymptomatic for 9, 10, and 15 months, respectively. In summary, Sandostatin decreased persistent catheter drainage from chronic pancreatic pseudocysts.

KW - Catheter drainage

KW - Needle aspiration

KW - Pancreatic pseudocyst

KW - Pancreatic secretion

KW - Sandostatin

UR - http://www.scopus.com/inward/record.url?scp=0026033935&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026033935&partnerID=8YFLogxK

M3 - Article

C2 - 1886893

AN - SCOPUS:0026033935

VL - 6

SP - 245

EP - 248

JO - Pancreas

JF - Pancreas

SN - 0885-3177

IS - 2

ER -